<p>Suven Life Sciences, Hyderabad India based pharmaceutical company gets patent approval from Newzealand and Norway for its product related with Neurogenerative Disease treatment. </p><p>The company informed that, these patents are valid till 2034 and 2027, respectively, the company said in a BSE filing. </p>rnrn<blockquote><p> The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer&#039;s disease, attention deficient hyperactivity disorder (ADHD), Huntington&#039;s disease, Parkinson&#039;s and schizophrenia, it added. .</p></blockquote><p>"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said. </p>rnrn<p>The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer&#039;s disease, attention deficient hyperactivity disorder (ADHD), Huntington&#039;s disease, Parkinson&#039;s and schizophrenia, it added. </p>